Global Molecular Radiotherapy Dosimetry Market

Molecular Radiotherapy Dosimetry Comprehensive Study by End users (Hospitals, Cancer research centre, Research laboratories), Technology (Cloud based, In-house bases), Radiotherapy (Y-90 SIRT, Radium-223, Lu-177 DOTATATE) Players and Region - Global Market Outlook to 2027

Molecular Radiotherapy Dosimetry Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Molecular radiotherapy dosimetry is the combination of measurement and calculation of the absorbed dose of ionizing radiation in malignant tissue, which would give a contrasting outlook in comparison to absorption done by healthy tissue. Molecular radiotherapy dosimetry is usually prescribed fixed therapy adjusted for body mass. Molecular radiotherapy dosimetry therapy is for cancer, benign diseases, and malignant diseases. Additionally treatment decisions for bone metastases are carried by molecular radiotherapy dosimetry.

Market Drivers
  • Increasing Number of Breast Cancer and Prostate Cancer Patients

Market Trend
  • Improved Radiographic Imaging Technology and Innovations in, Guidewires, Catheters Stents, and Biomaterials

Restraints
  • Due To High Absorbed Dose Kills Normal Tissues

Opportunities
Growing Positive Healthcare Infrastructure and New Techniques

Players Covered in the Study are:
MIM Software Inc. (United States), DOSIsoft SA (France), Novartis International AG (Switzerland), Mirada Medical Ltd (United Kingdom), Ashland (United States), Sirtex Medical (Australia), mirada medical ltd (United Kingdom) and Elekta (Sweden)

The Global Molecular Radiotherapy Dosimetry market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

What can be explored with Molecular Radiotherapy Dosimetry study:
• Where Molecular Radiotherapy Dosimetry industry stands in scaling its end use implementations
• What concrete benefits would result from scaled initiatives by Players
• Where Players should focus their investments cycle
• Key success factors and recommendations for upscaling future growth.
• Target Market / Country and Key Business Segments



Report Objectives / Segmentation Covered

By End users
  • Hospitals
  • Cancer research centre
  • Research laboratories

By Technology
  • Cloud based
  • In-house bases

By Radiotherapy
  • Y-90 SIRT
  • Radium-223
  • Lu-177 DOTATATE

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Breast Cancer and Prostate Cancer Patients
    • 3.3. Market Challenges
      • 3.3.1. Significant Effect on Healthcare Funding, Patient Management
    • 3.4. Market Trends
      • 3.4.1. Improved Radiographic Imaging Technology and Innovations in, Guidewires, Catheters Stents, and Biomaterials
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Molecular Radiotherapy Dosimetry, by End users, Technology, Radiotherapy and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Molecular Radiotherapy Dosimetry (Value)
      • 5.2.1. Global Molecular Radiotherapy Dosimetry by: End users (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Cancer research centre
        • 5.2.1.3. Research laboratories
      • 5.2.2. Global Molecular Radiotherapy Dosimetry by: Technology (Value)
        • 5.2.2.1. Cloud based
        • 5.2.2.2. In-house bases
      • 5.2.3. Global Molecular Radiotherapy Dosimetry by: Radiotherapy (Value)
        • 5.2.3.1. Y-90 SIRT
        • 5.2.3.2. Radium-223
        • 5.2.3.3. Lu-177 DOTATATE
      • 5.2.4. Global Molecular Radiotherapy Dosimetry Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Molecular Radiotherapy Dosimetry (Price)
  • 6. Molecular Radiotherapy Dosimetry: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. MIM Software Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. DOSIsoft SA (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mirada Medical Ltd (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ashland (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sirtex Medical (Australia)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mirada medical ltd (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Elekta (Sweden)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Molecular Radiotherapy Dosimetry Sale, by End users, Technology, Radiotherapy and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Molecular Radiotherapy Dosimetry (Value)
      • 7.2.1. Global Molecular Radiotherapy Dosimetry by: End users (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Cancer research centre
        • 7.2.1.3. Research laboratories
      • 7.2.2. Global Molecular Radiotherapy Dosimetry by: Technology (Value)
        • 7.2.2.1. Cloud based
        • 7.2.2.2. In-house bases
      • 7.2.3. Global Molecular Radiotherapy Dosimetry by: Radiotherapy (Value)
        • 7.2.3.1. Y-90 SIRT
        • 7.2.3.2. Radium-223
        • 7.2.3.3. Lu-177 DOTATATE
      • 7.2.4. Global Molecular Radiotherapy Dosimetry Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Molecular Radiotherapy Dosimetry (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Molecular Radiotherapy Dosimetry: by End users(USD Million)
  • Table 2. Molecular Radiotherapy Dosimetry Hospitals , by Region USD Million (2016-2021)
  • Table 3. Molecular Radiotherapy Dosimetry Cancer research centre , by Region USD Million (2016-2021)
  • Table 4. Molecular Radiotherapy Dosimetry Research laboratories , by Region USD Million (2016-2021)
  • Table 5. Molecular Radiotherapy Dosimetry: by Technology(USD Million)
  • Table 6. Molecular Radiotherapy Dosimetry Cloud based , by Region USD Million (2016-2021)
  • Table 7. Molecular Radiotherapy Dosimetry In-house bases , by Region USD Million (2016-2021)
  • Table 8. Molecular Radiotherapy Dosimetry: by Radiotherapy(USD Million)
  • Table 9. Molecular Radiotherapy Dosimetry Y-90 SIRT , by Region USD Million (2016-2021)
  • Table 10. Molecular Radiotherapy Dosimetry Radium-223 , by Region USD Million (2016-2021)
  • Table 11. Molecular Radiotherapy Dosimetry Lu-177 DOTATATE , by Region USD Million (2016-2021)
  • Table 12. South America Molecular Radiotherapy Dosimetry, by Country USD Million (2016-2021)
  • Table 13. South America Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 14. South America Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 15. South America Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 16. Brazil Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 17. Brazil Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 18. Brazil Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 19. Argentina Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 20. Argentina Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 21. Argentina Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 22. Rest of South America Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 23. Rest of South America Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 24. Rest of South America Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 25. Asia Pacific Molecular Radiotherapy Dosimetry, by Country USD Million (2016-2021)
  • Table 26. Asia Pacific Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 27. Asia Pacific Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 28. Asia Pacific Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 29. China Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 30. China Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 31. China Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 32. Japan Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 33. Japan Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 34. Japan Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 35. India Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 36. India Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 37. India Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 38. South Korea Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 39. South Korea Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 40. South Korea Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 41. Australia Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 42. Australia Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 43. Australia Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 44. Rest of Asia-Pacific Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 45. Rest of Asia-Pacific Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 46. Rest of Asia-Pacific Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 47. Europe Molecular Radiotherapy Dosimetry, by Country USD Million (2016-2021)
  • Table 48. Europe Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 49. Europe Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 50. Europe Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 51. Germany Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 52. Germany Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 53. Germany Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 54. France Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 55. France Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 56. France Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 57. Italy Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 58. Italy Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 59. Italy Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 60. United Kingdom Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 61. United Kingdom Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 62. United Kingdom Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 63. Netherlands Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 64. Netherlands Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 65. Netherlands Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 66. Rest of Europe Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 67. Rest of Europe Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 68. Rest of Europe Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 69. MEA Molecular Radiotherapy Dosimetry, by Country USD Million (2016-2021)
  • Table 70. MEA Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 71. MEA Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 72. MEA Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 73. Middle East Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 74. Middle East Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 75. Middle East Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 76. Africa Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 77. Africa Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 78. Africa Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 79. North America Molecular Radiotherapy Dosimetry, by Country USD Million (2016-2021)
  • Table 80. North America Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 81. North America Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 82. North America Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 83. United States Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 84. United States Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 85. United States Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 86. Canada Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 87. Canada Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 88. Canada Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 89. Mexico Molecular Radiotherapy Dosimetry, by End users USD Million (2016-2021)
  • Table 90. Mexico Molecular Radiotherapy Dosimetry, by Technology USD Million (2016-2021)
  • Table 91. Mexico Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2016-2021)
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Molecular Radiotherapy Dosimetry: by End users(USD Million)
  • Table 101. Molecular Radiotherapy Dosimetry Hospitals , by Region USD Million (2022-2027)
  • Table 102. Molecular Radiotherapy Dosimetry Cancer research centre , by Region USD Million (2022-2027)
  • Table 103. Molecular Radiotherapy Dosimetry Research laboratories , by Region USD Million (2022-2027)
  • Table 104. Molecular Radiotherapy Dosimetry: by Technology(USD Million)
  • Table 105. Molecular Radiotherapy Dosimetry Cloud based , by Region USD Million (2022-2027)
  • Table 106. Molecular Radiotherapy Dosimetry In-house bases , by Region USD Million (2022-2027)
  • Table 107. Molecular Radiotherapy Dosimetry: by Radiotherapy(USD Million)
  • Table 108. Molecular Radiotherapy Dosimetry Y-90 SIRT , by Region USD Million (2022-2027)
  • Table 109. Molecular Radiotherapy Dosimetry Radium-223 , by Region USD Million (2022-2027)
  • Table 110. Molecular Radiotherapy Dosimetry Lu-177 DOTATATE , by Region USD Million (2022-2027)
  • Table 111. South America Molecular Radiotherapy Dosimetry, by Country USD Million (2022-2027)
  • Table 112. South America Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 113. South America Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 114. South America Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 115. Brazil Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 116. Brazil Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 117. Brazil Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 118. Argentina Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 119. Argentina Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 120. Argentina Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 121. Rest of South America Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 122. Rest of South America Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 123. Rest of South America Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 124. Asia Pacific Molecular Radiotherapy Dosimetry, by Country USD Million (2022-2027)
  • Table 125. Asia Pacific Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 126. Asia Pacific Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 127. Asia Pacific Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 128. China Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 129. China Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 130. China Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 131. Japan Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 132. Japan Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 133. Japan Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 134. India Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 135. India Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 136. India Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 137. South Korea Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 138. South Korea Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 139. South Korea Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 140. Australia Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 141. Australia Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 142. Australia Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 143. Rest of Asia-Pacific Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 144. Rest of Asia-Pacific Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 145. Rest of Asia-Pacific Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 146. Europe Molecular Radiotherapy Dosimetry, by Country USD Million (2022-2027)
  • Table 147. Europe Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 148. Europe Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 149. Europe Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 150. Germany Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 151. Germany Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 152. Germany Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 153. France Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 154. France Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 155. France Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 156. Italy Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 157. Italy Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 158. Italy Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 159. United Kingdom Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 160. United Kingdom Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 161. United Kingdom Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 162. Netherlands Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 163. Netherlands Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 164. Netherlands Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 165. Rest of Europe Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 166. Rest of Europe Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 167. Rest of Europe Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 168. MEA Molecular Radiotherapy Dosimetry, by Country USD Million (2022-2027)
  • Table 169. MEA Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 170. MEA Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 171. MEA Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 172. Middle East Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 173. Middle East Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 174. Middle East Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 175. Africa Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 176. Africa Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 177. Africa Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 178. North America Molecular Radiotherapy Dosimetry, by Country USD Million (2022-2027)
  • Table 179. North America Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 180. North America Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 181. North America Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 182. United States Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 183. United States Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 184. United States Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 185. Canada Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 186. Canada Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 187. Canada Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 188. Mexico Molecular Radiotherapy Dosimetry, by End users USD Million (2022-2027)
  • Table 189. Mexico Molecular Radiotherapy Dosimetry, by Technology USD Million (2022-2027)
  • Table 190. Mexico Molecular Radiotherapy Dosimetry, by Radiotherapy USD Million (2022-2027)
  • Table 191. Research Programs/Design for This Report
  • Table 192. Key Data Information from Secondary Sources
  • Table 193. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Molecular Radiotherapy Dosimetry: by End users USD Million (2016-2021)
  • Figure 5. Global Molecular Radiotherapy Dosimetry: by Technology USD Million (2016-2021)
  • Figure 6. Global Molecular Radiotherapy Dosimetry: by Radiotherapy USD Million (2016-2021)
  • Figure 7. South America Molecular Radiotherapy Dosimetry Share (%), by Country
  • Figure 8. Asia Pacific Molecular Radiotherapy Dosimetry Share (%), by Country
  • Figure 9. Europe Molecular Radiotherapy Dosimetry Share (%), by Country
  • Figure 10. MEA Molecular Radiotherapy Dosimetry Share (%), by Country
  • Figure 11. North America Molecular Radiotherapy Dosimetry Share (%), by Country
  • Figure 12. Global Molecular Radiotherapy Dosimetry share by Players 2021 (%)
  • Figure 13. Global Molecular Radiotherapy Dosimetry share by Players (Top 3) 2021(%)
  • Figure 14. Global Molecular Radiotherapy Dosimetry share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. MIM Software Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. MIM Software Inc. (United States) Revenue: by Geography 2021
  • Figure 18. DOSIsoft SA (France) Revenue, Net Income and Gross profit
  • Figure 19. DOSIsoft SA (France) Revenue: by Geography 2021
  • Figure 20. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis International AG (Switzerland) Revenue: by Geography 2021
  • Figure 22. Mirada Medical Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Mirada Medical Ltd (United Kingdom) Revenue: by Geography 2021
  • Figure 24. Ashland (United States) Revenue, Net Income and Gross profit
  • Figure 25. Ashland (United States) Revenue: by Geography 2021
  • Figure 26. Sirtex Medical (Australia) Revenue, Net Income and Gross profit
  • Figure 27. Sirtex Medical (Australia) Revenue: by Geography 2021
  • Figure 28. Mirada medical ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. Mirada medical ltd (United Kingdom) Revenue: by Geography 2021
  • Figure 30. Elekta (Sweden) Revenue, Net Income and Gross profit
  • Figure 31. Elekta (Sweden) Revenue: by Geography 2021
  • Figure 32. Global Molecular Radiotherapy Dosimetry: by End users USD Million (2022-2027)
  • Figure 33. Global Molecular Radiotherapy Dosimetry: by Technology USD Million (2022-2027)
  • Figure 34. Global Molecular Radiotherapy Dosimetry: by Radiotherapy USD Million (2022-2027)
  • Figure 35. South America Molecular Radiotherapy Dosimetry Share (%), by Country
  • Figure 36. Asia Pacific Molecular Radiotherapy Dosimetry Share (%), by Country
  • Figure 37. Europe Molecular Radiotherapy Dosimetry Share (%), by Country
  • Figure 38. MEA Molecular Radiotherapy Dosimetry Share (%), by Country
  • Figure 39. North America Molecular Radiotherapy Dosimetry Share (%), by Country
List of companies from research coverage that are profiled in the study
  • MIM Software Inc. (United States)
  • DOSIsoft SA (France)
  • Novartis International AG (Switzerland)
  • Mirada Medical Ltd (United Kingdom)
  • Ashland (United States)
  • Sirtex Medical (Australia)
  • mirada medical ltd (United Kingdom)
  • Elekta (Sweden)
Select User Access Type

Key Highlights of Report


Jan 2022 247 Pages 84 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Molecular Radiotherapy Dosimetry Market Quantitative research analysis
Global Molecular Radiotherapy Dosimetry Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Molecular Radiotherapy Dosimetry market is expected to see a CAGR of % during projected year 2021 to 2027.
Top performing companies in the Global Molecular Radiotherapy Dosimetry market are MIM Software Inc. (United States), DOSIsoft SA (France), Novartis International AG (Switzerland), Mirada Medical Ltd (United Kingdom), Ashland (United States), Sirtex Medical (Australia), mirada medical ltd (United Kingdom) and Elekta (Sweden), to name a few.
"Improved Radiographic Imaging Technology and Innovations in, Guidewires, Catheters Stents, and Biomaterials" is seen as one of major influencing trends for Molecular Radiotherapy Dosimetry Market during projected period 2021-2027.

Know More About Global Molecular Radiotherapy Dosimetry Market Report?

Have a Query? Click Here

Other Related Reports

Intelligent and Health Care Comprehensive Study by Type (Machine Learning, Natural Language Processing, Rule-Based Expert Systems, Physical Robots, Robotic Process Automation), Application (Drug Deve...
$ 3750
Patient Health Management Comprehensive Study by Application (Hospitals, Clinics), Feature (Online scheduling, Laboratory information system, Blood bank, In-Patient Services, Out-patient services, Ot...
$ 3800
Antisense Therapy Comprehensive Study by Route of Administration (Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal injections, Topical Delivery, Other), End-users ...
$ 3500
Mobile Veterinary Care Comprehensive Study by Services (Video Consultation, Home Visits, Pet Medication, Others), Treatment (Dental Health, Eye Health, Ear Health, General Checkup, Others), Pet Type ...
$ 3400
Myotonic Dystrophy Treatment Comprehensive Study by Type (Congenital-onset, Childhood- or juvenile-onset, Adult-onset, Mild), Treatment (Devices, Medications, Rehabilitative Therapy, Surgery), End-us...
$ 3800
Telehealth Technology Comprehensive Study by Application (Teleradiology, Telepsychiatry, Telepathology, Teledermatology, Telecardiology, Others), End-user (Healthcare Providers, Payers, Patients, Ot...
$ 4000